[FGEN] FibroGen, Inc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 20.8 Change: 1.3 (6.67%)
Ext. hours: Change: 0 (0%)

chart FGEN

Refresh chart

Strongest Trends Summary For FGEN

FGEN is in the long-term up 116% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: FibroGen, Inc. discovers, develops, and commercializes drugs for anemia and pulmonary fibrosis. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was founded in 1993 and is headquartered in San Francisco, California.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 19.29% Sales Growth - Q/Q1.2% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-31.33% ROE-73.92% ROI-45.95%
Current Ratio2.88 Quick Ratio Long Term Debt/Equity0.95 Debt Ratio0.29
Gross Margin Operating Margin-281.76% Net Profit Margin-296.24% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities620 K Cash From Investing Activities4.55 M Cash From Operating Activities-42.19 M Gross Profit
Net Profit-46.37 M Operating Profit-44.72 M Total Assets435.54 M Total Current Assets155.4 M
Total Current Liabilities53.96 M Total Debt111.65 M Total Liabilities250.92 M Total Revenue16.3 M
Technical Data
High 52 week67.25 Low 52 week37.97 Last close58.53 Last change2.65%
RSI58.24 Average true range1.95 Beta1.53 Volume241.17 K
Simple moving average 20 days3.09% Simple moving average 50 days16.53% Simple moving average 200 days8.85%
Performance Data
Performance Week0.05% Performance Month9.48% Performance Quart48.63% Performance Half-5.29%
Performance Year4.15% Performance Year-to-date26.47% Volatility daily1.98% Volatility weekly4.42%
Volatility monthly9.06% Volatility yearly31.39% Relative Volume223.58% Average Volume638.76 K
New High New Low

News

2019-04-15 07:00:00 | FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

2019-04-10 10:30:02 | Akebia Expands Vadadustat Licensing Deal With Vifor Pharma

2019-04-08 15:38:18 | Is FibroGen, Inc. NASDAQ:FGEN A Financially Strong Company?

2019-04-03 10:48:02 | Options Traders Expect Huge Moves in FibroGen FGEN Stock

2019-04-02 07:07:00 | 4 Biotech Stocks With Major Catalysts in April

2019-03-07 14:16:10 | FibroGen, Inc. NASDAQ:FGEN: Commentary On Fundamentals

2019-03-05 16:06:09 | What's in the Cards for Corbus CRBP This Earnings Season?

2019-03-01 13:57:16 | What Wall Street Recommends for Amarin after Q4 2018 Results

2019-03-01 06:36:49 | Edited Transcript of FGEN earnings conference call or presentation 27-Feb-19 10:00pm GMT

2019-02-28 00:45:06 | FibroGen Inc FGEN Q4 2018 Earnings Conference Call Transcript

2019-02-27 16:08:12 | FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-22 23:43:13 | FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-22 16:36:09 | What's in Store for Teladoc's TDOC Q4 Earnings?

2019-02-20 09:32:02 | Tenet Healthcare THC Q4 Earnings: What's in the Offing?

2019-02-08 08:03:40 | See what the IHS Markit Score report has to say about FibroGen Inc.

2019-02-06 10:50:01 | How Much is FibroGen, Inc.’s NASDAQ:FGEN CEO Getting Paid?

2019-01-29 08:04:08 | See what the IHS Markit Score report has to say about FibroGen Inc.

2019-01-17 08:01:54 | See what the IHS Markit Score report has to say about FibroGen Inc.

2019-01-17 08:00:00 | Today's Research Reports on Trending Tickers: Ligand Pharmaceuticals and FibroGen

2019-01-17 07:35:00 | Analysis: Positioning to Benefit within Motorola Solutions, FibroGen, UnitedHealth Group, Newell Brands, Vuzix, and Choice Hotels International — Research Highlights Growth, Revenue, and Consolidated Results

2019-01-09 08:03:59 | See what the IHS Markit Score report has to say about FibroGen Inc.

2018-12-20 16:14:43 | Can This Biotech Stock Rival Amgen In Anemia? Analyst Says Yes

2018-12-20 09:09:00 | AstraZeneca stock up 2.8% after announcing EU approval of COPD treatment

2018-12-20 08:02:27 | See what the IHS Markit Score report has to say about FibroGen Inc.

2018-12-20 07:00:00 | Today's Research Reports on Trending Tickers: Aimmune Therapeutics and FibroGen

2018-12-20 07:00:00 | FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease

2018-12-19 01:21:12 | FibroGen Inc FGEN: Hedge Fund Sentiment Unchanged

2018-12-18 20:21:58 | [$$] Big Pharma Wins Drug Approval in China Ahead of West for First Time

2018-12-18 17:18:43 | Why a kidney disease drug approval in China is just the start for this S.F. company

2018-12-18 08:00:31 | The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan

2018-12-18 06:24:52 | China first to approve AstraZeneca, FibroGen anaemia drug

2018-12-17 18:07:44 | FibroGen Announces Approval of Roxadustat in China for the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis

2018-12-17 12:21:09 | How Many Insiders Sold FibroGen, Inc. NASDAQ:FGEN Shares?

2018-12-06 04:00:00 | FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors

2018-11-27 08:45:00 | New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-11-24 08:05:47 | See what the IHS Markit Score report has to say about FibroGen Inc.

2018-11-22 08:05:55 | See what the IHS Markit Score report has to say about FibroGen Inc.

2018-11-14 06:55:00 | Today's Research Reports on Trending Tickers: Amicus Therapeutics and FibroGen

2018-11-13 08:05:56 | See what the IHS Markit Score report has to say about FibroGen Inc.

2018-11-09 03:17:07 | Edited Transcript of FGEN earnings conference call or presentation 8-Nov-18 10:00pm GMT

2018-11-08 18:40:11 | FibroGen FGEN Reports Q3 Loss, Lags Revenue Estimates

2018-11-08 17:35:50 | FibroGen: 3Q Earnings Snapshot

2018-11-08 16:02:00 | FibroGen Reports Third Quarter 2018 Financial Results

2018-11-06 08:02:22 | See what the IHS Markit Score report has to say about FibroGen Inc.

2018-11-05 13:55:56 | What Kind Of Shareholder Appears On The FibroGen Inc’s NASDAQ:FGEN Shareholder Register?

2018-11-02 17:02:51 | FibroGen to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018

2018-10-30 04:00:00 | ASN Kidney Week 2018: Data Presented from Two Japanese Phase 3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis

2018-10-25 19:49:27 | FibroGen Presents Results from Two Phase 3 Studies of Roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease Conducted in China at American Society of Nephrology Kidney Week 2018 Annual Meeting

2018-10-18 08:00:00 | Today's Research Reports on Trending Tickers: Immunomedics and FibroGen

2018-10-16 16:27:29 | FibroGen Announces Four Clinical Presentations on Roxadustat at Upcoming American Society of Nephrology Kidney Week 2018 Annual Meeting